Brainstorm Cell Therapeutics Inc. (BCLI)
EBITDA Growth
-41.44%
Quarterly · Period ending:
BCLI EBITDA Growth
Year-over-year change vs the same period a year earlier
Latest reported-41.44%period ending
Latest reported-41.44%period ending
BCLI Quarterly EBITDA YoY % (-16.57% → -41.44%)
Year-over-year change
High-resolution chart · PNG
BCLI ebitda growth history
Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | EBITDA Growth |
|---|---|
| -41.4354% | |
| 33.8492% | |
| 29.9745% | |
| 33.1214% | |
| 13.5709% | |
| -26.0166% | |
| 43.106% | |
| 49.933% | |
| 45.7822% | |
| 52.5964% | |
| -13.7668% | |
| 11.8299% | |
| 28.4309% | |
| 5.8693% | |
| 21.1169% | |
| -29.9616% | |
| -24.1129% | |
| 21.3599% | |
| 46.2501% | |
| -17.6338% | |
| 17.5646% | |
| 16.8422% | |
| -50.0591% | |
| 19.6772% | |
| -52.3632% | |
| -69.1032% | |
| -40.6019% | |
| -72.3664% | |
| -57.8534% | |
| -114.0228% | |
| -2,136.0902% | |
| -35.0359% | |
| -189.1202% | |
| -30.1026% | |
| 142.3567% | |
| -46.1444% | |
| -9.9896% | |
| 2.3385% | |
| 54.5915% | |
| 36.3065% | |
| 58.9141% | |
| 17.6902% | |
| 47.6533% | |
| -6.0417% | |
| -84.3184% | |
| -116.8986% | |
| -92.0058% | |
| -128.7893% | |
| 13.5559% | |
| 4.0076% | |
| -166.6667% | |
| 7.4139% | |
| -76.2305% | |
| -24.6136% | |
| 58.1848% | |
| -61.8571% | |
| 39.5062% | |
| -71.6327% | |
| -128.5185% | |
| -18.0438% | |
| -123.539% | |
| 19.5402% | |
| -480.6452% | |
| 0% | |
| -17.5573% | |
| -12.7778% | |
| -167.8832% | |
| 14.9211% | |
| 7.4205% | |
| 37.6443% | |
| 123.1029% | |
| 14.5833% | |
| -52.1906% | |
| -22.9562% | |
| 65.5106% | |
| -93.1078% | |
| 12.261% | |
| -226.4955% | |
| -2,529.2087% | |
| 33.9502% | |
| 17.1268% | |
| 12.2786% | |
| 99.6061% | |
| 59.3707% | |
| -5,780.3403% | |
| -806.6659% | |
| -191,407.1404% | |
| -30,726.8207% | |
| -37.3441% | |
| -929.3359% | |
| -81.7782% | |
| -47.8437% | |
| -16.5654% |